8-K - Beam Therapeutics Inc. (0001745999) (Filer)
Published . Updated .
Key takeaways
- 8-K - Beam Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: BEAM
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Beam Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- BEAM Beam Therapeutics+1.0% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Beam Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+13.5% 30d
Amgen is a peer of Beam Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.4% 30d
Gilead Sciences is a peer of Beam Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+21.1% 30d
Moderna is a peer of Beam Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-16.4% 16d
argenx SE is a peer of Beam Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Beam Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BEAM | -3.60% | +11.65% | base | after close | after close | after close | after close |
| XLV | -2.95% | -0.31% | base | after close | after close | after close | after close |
| AMGN | -3.75% | -1.04% | base | after close | after close | after close | after close |
| GILD | -6.65% | -2.82% | base | after close | after close | after close | after close |
| MRNA | -5.90% | +0.84% | base | after close | after close | after close | after close |
| ARGX | +0.87% | +2.64% | base | after close | after close | after close | after close |
| RVMD | -1.02% | +1.20% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001193125-26-444454 Size: 439 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
How far Beam Therapeutics (BEAM) has moved since 3 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | three days earlier | -1.04% | final price |
| AMGN | five days earlier | -3.75% | final price |
| ARGX | three days earlier | +2.64% | final price |
| ARGX | five days earlier | +0.87% | final price |
| Beam Therapeutics (BEAM) | three days earlier | +11.65% | final price |
| Beam Therapeutics (BEAM) | five days earlier | -3.60% | final price |
| GILD | three days earlier | -2.82% | final price |
| GILD | five days earlier | -6.65% | final price |
| MRNA | three days earlier | +0.84% | final price |
| MRNA | five days earlier | -5.90% | final price |
| RVMD | three days earlier | +1.20% | final price |
| RVMD | five days earlier | -1.02% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 83 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 67 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Beam Therapeutics Inc. (0001745999) (Filer)”
Companies mentioned with this story
- BEAM Beam Therapeutics
For “8-K - Beam Therapeutics Inc. (0001745999) (Filer),” Beam Therapeutics (BEAM) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> BEAM
How “8-K - Beam Therapeutics Inc. (0001745999) (Filer)” reaches Beam Therapeutics (BEAM)
On 3 Nov 2026, “8-K - Beam Therapeutics Inc. (0001745999) (Filer)” is the story that connects Beam Therapeutics (BEAM) to this story.
What ties Beam Therapeutics (BEAM) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> BEAM
Dates and price levels for Beam Therapeutics (BEAM)
BEAM traded between 23.16 and 26.92 across 20 sessions. The latest close on file is 23.49.
A simple score for Beam Therapeutics (BEAM)
14 out of 100
“8-K - Beam Therapeutics Inc. (0001745999) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.